Breaking News, Promotions & Moves

Cytovance Biologics

Bernhard Hampl, Ph.D., has been appointed co-chairman of Cytovance Biologics, Inc.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Bernhard Hampl, Ph.D., has been appointed co-chairman of Cytovance Biologics, Inc. Previously, he served as chief executive officer of Eon Labs and the Sandoz U.S. division of Novartis. Dr. Hampl joined Eon as chief executive officer and president in 1996 and led the company’s growth transformation and subsequent acquisition by Novartis in 2005. Darren Head, chief executive officer of Cytovance said, “Cytovance has been experiencing rapid business growth and the equity financing from Great P...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters